SINAPPS stands for Study of Immunology in Antibody Positive Psychosis.

We are a research group formed of collaborating Universities in the UK, investigating the role of immunotherapy and autoimmune antibodies as a cause of psychosis.

About SINAPPS Group

Our group's research spans a number of universities and hospitals in England, but was founded by researchers at the Universities of Oxford and Cambridge.

Where are we based?

Cambridge School of Clinical Medicine is the East of England SINAPPS2 hub, where two memebrs of the SINAPPS group, Professor Alasdair Coles (SINAPPS2 Chief Investigator and SINAPPS2 PI for Cambridge University Hospitals NHS Foundation Trust site) and Professor Peter Jones, are based.


University of Oxford

University of Cambridge


Dr Michael Zandi is a honorary consultant neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square in London and and UCLH NHS Trust.


He is also the SINAPPS2 trial principal investigator at the National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust.

University College London

The Department of Psychiatry's Early Psychosis Research Group is the Oxford SINAPPS hub, headed by Professor Belinda Lennox.


Professor Lennox is Principal Investigator of the SINAPPS2 Oxford trial site at John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust.


The antibody testing portion of both PPiP2 and SINAPPS2 studies are carried out at Professor Angela Vincent's neuroimmunology laboratory, Department of Clinical Neuroscience.


The senior SINAPPS group members are supported in delivering the SINAPPS2 trial by a team of senior academics, consultant neurologists, trial coordinators and research assistants. Click here to learn about the staff currently involved in running the SINAPPS2 study.  


The SINAPPS2 trial was designed with the contribution of The McPin Foundation, a research charity dedicated to putting the lived experience of people affected by mental health problems at the heart of the research agenda.

SINAPPS2 trial team